About Alligator Bioscience
Alligator Bioscience is a company based in Lund (Sweden) founded in 2001. It operates as a HealthTech. Alligator Bioscience has raised $10 million across 2 funding rounds from investors including Vinnova. Alligator Bioscience offers products and services including Mitazalimab, ATOR-4066, and ALG.APV-527. Alligator Bioscience operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Revolution Medicines, among others.
- Headquarter Lund, Sweden
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Alligator Bioscience Ab
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$10 M (USD)
in 2 rounds
-
Latest Funding Round
$55.05 K (USD), Grant
Oct 05, 2018
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Alligator Bioscience
Alligator Bioscience offers a comprehensive portfolio of products and services, including Mitazalimab, ATOR-4066, and ALG.APV-527.
Developed as a tumor-directed immunotherapy for cancer treatment.
Designed as an antibody-based solution for cancer therapy.
Created for targeted cancer treatment using antibody technology.
People of Alligator Bioscience
Unlock access to complete
Unlock access to complete
Funding Insights of Alligator Bioscience
Alligator Bioscience has successfully raised a total of $10M across 2 strategic funding rounds. The most recent funding activity was a Grant round of $55.05 thousand completed in October 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Alligator Bioscience
Alligator Bioscience has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Vinnova.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital funding is provided to Swedish companies across sectors.
|
Locked | Locked | Locked |
Investor details for Alligator Bioscience
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Alligator Bioscience
Investment portfolio details for Alligator Bioscience
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Alligator Bioscience
Detailed financials for Alligator Bioscience
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Alligator Bioscience Comparisons
Peer comparison for Alligator Bioscience
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Alligator Bioscience
Alligator Bioscience operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Revolution Medicines, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
Detailed competitors of Alligator Bioscience
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Alligator Bioscience
Complete news archive for Alligator Bioscience
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Alligator Bioscience
Alligator Bioscience was founded in 2001 and raised its 1st funding round 14 years after it was founded.
Alligator Bioscience is headquartered in Lund, Sweden.
Alligator Bioscience is a funded company, having raised a total of $10M across 2 funding rounds to date.
Alligator Bioscience is engaged in the development of antibody-based pharmaceuticals for cancer treatment. The company is specialized in tumor-directed immunotherapies, particularly agonistic mono- and bispecific antibodies. Solutions are developed within the biotechnology sector, targeting innovative approaches to combat metastatic cancers like pancreatic cancer. Research and development efforts are centered on a pipeline of candidates such as Mitazalimab, ATOR-4066, and ALG.APV-527, aimed at improving patient outcomes through advanced therapeutic technologies.
Alligator Bioscience's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Alligator Bioscience offers Mitazalimab, ATOR-4066, and ALG.APV-527.
Alligator Bioscience has 1 investor. Key investors include Vinnova.